Page last updated: 2024-11-12
cyperotundone
Description
cyperotundone: from Cyperus rotundus L.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Cyperus | genus | A plant genus of the family CYPERACEAE. SESQUITERPENES are found in some of the species.[MeSH] | Cyperaceae | The sedge plant family of the order Cyperales, subclass Commelinidae, class Liliopsida (monocotyledons)[MeSH] |
| Cyperus rotundus | species | [no description available] | Cyperaceae | The sedge plant family of the order Cyperales, subclass Commelinidae, class Liliopsida (monocotyledons)[MeSH] |
Cross-References
Synonyms (7)
| Synonym |
|---|
| C17501 |
| cyperotundone |
| CHEBI:81137 |
| 4,10,11,11-tetramethyltricyclo[5.3.1.0^{1,5}]undec-4-en-3-one |
| Q27155094 |
| FT-0775620 |
| 4,10,11,11-tetramethyltricyclo[5.3.1.01,5]undec-4-en-3-one |
Research Excerpts
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|
| " Overall, our findings showed that CYT in combination with ADR has potent anti-breast cancer cell activity both in vivo and in vitro, suggesting CYT as the main drug used to improve chemosensitivity." | ( Cyperotundone combined with adriamycin induces apoptosis in MCF-7 and MCF-7/ADR cancer cells by ROS generation and NRF2/ARE signaling pathway.
Liu, X; Liu, Z; Shao, W; Song, X; Wang, F; Wang, X; Yu, Z, 2023) | 2.35 |
Drug Classes (1)
| Class | Description |
|---|
| sesquiterpenoid | Any terpenoid derived from a sesquiterpene. The term includes compounds in which the C15 skeleton of the parent sesquiterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 23.36
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 23.36 (24.57) | | Research Supply Index | 1.95 (2.92) | | Research Growth Index | 4.72 (4.65) | | Search Engine Demand Index | 21.17 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |